Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
This study has been completed.
Study NCT00210769 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received on September 13, 2005. Last Updated on May 17, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
paliperidone ER Oros
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers